Aspen Neuroscience (ASPE.US), a developer of Parkinson’s disease therapies, sets IPO pricing at $15-17 per share, aiming to raise $150 million

According to Golden Ten Data, Aspen Neuroscience, a clinical-stage biotechnology company developing stem cell therapies for Parkinson's disease, announced its IPO terms on Monday. The San Diego, California-based company plans to offer 9.4 million shares at a price range of $15 to $17 per share, aiming to raise $150 million. Based on the midpoint of the proposed price range, Aspen Neuroscience's fully diluted market value would be approximately $494 million.